Cellyan Biotechnology Co., Ltd cash flow to debt ratio of -59.74% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cellyan Biotechnology Co., Ltd's free cash flow has decreased 290.01% from $414.23K last year to $-787.07K, signaling decreasing performance

Cellyan Biotechnology Co., Ltd's debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

Cellyan Biotechnology Co., Ltd's debt has decreased relative to shareholder equity from 0.48 last year to 0.13 today, signaling strengthened financials

Cellyan Biotechnology Co., Ltd has negative EBITDA, making leverage ratio unreliable

Cellyan Biotechnology Co., Ltd's interest coverage ratio is -7.46, which means that the company struggles to meet interest obligations, signaling financial risk.

Cellyan Biotechnology Co., Ltd's profit margin was -0.13% last year and is -8.46% this year, signaling decreasing performance

Cellyan Biotechnology Co., Ltd's short-term assets of $12.33M exceed its short-term liabilities of $3.20M

Cellyan Biotechnology Co., Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cellyan Biotechnology Co., Ltd's return on equity of -15.43%, is lower than 15.00%, indicating bad performance

Cellyan Biotechnology Co., Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate earnings stability.

Cellyan Biotechnology Co., Ltd has negative free cash flow, indicating the company is burning cash rather than generating it

Cellyan Biotechnology Co., Ltd has negative free cash flow, indicating cash burn

Cellyan Biotechnology Co., Ltd's yearly earnings has decreased 4.10K% since last year from $-27.06K to $-1.14M, signaling decreasing performance

Cellyan Biotechnology Co., Ltd's yearly revenue has decreased 33.87% since last year from $20.31M to $13.43M, signaling decreasing performance

ROIC -9.18% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cellyan Biotechnology Co., Ltd's 3-year revenue CAGR of 2.28% is positive, indicating growing revenue over the past 3 years

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate revenue consistency.

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate ROE consistency.

Cellyan Biotechnology Co., Ltd has insufficient data to evaluate this check.

Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cellyan Biotechnology Co., Ltd is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Cellyan Biotechnology Co., Ltd has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cellyan Biotechnology Co., Ltd has insufficient data to evaluate this check.

Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cellyan Biotechnology Co., Ltd has a price-to-book ratio of 0.42x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cellyan Biotechnology Co., Ltd has a price-to-sales ratio of 0.30x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue